|
|
 |
|
Viewing report
|
|
 |
ARQULE - Read-Out Only in 2013
MP Advisors, Sep 2011
We remain positive on potential of Tivantinib (formerly ARQ-197, PhIII, c-MET inhibitor, 2nd/3rd-line NSCLC, partnered with Daiichi Sankyo, co-development, worldwide except Asia and Kyowa Hakko Kirin in Asia) but cautious on the B-RAF program, ARQ-736 (PhI, pan-Raf inhibitor, advanced solid tumors) based on our recent interaction with the management.
|
 |
|
|